title: A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist--Zoladex.
abstract: Luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in pre-menopausal women. Clinical responses are attributed to the suppression of the pituitary-ovarian axis, with a reduction in circulating levels of gonadal steroids similar to that produced by castration. In the present case report, we report a partial response to a LHRH analogue in a post-menopausal woman refractory to other endocrine treatments. This response cannot be explained with a chemical castration and confirms the possible direct anti-tumor effect of Zoladex.
authors.affiliation: Istituto di Clinica Medica, Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Cassano
authors.forename: A
authors.initials: A
authors.lastname: Astone
authors.forename: C
authors.initials: C
authors.lastname: Garufi
authors.forename: M R
authors.initials: MR
authors.lastname: Noviello
authors.forename: F
authors.initials: F
authors.lastname: Pietrantonio
authors.forename: C
authors.initials: C
authors.lastname: Barone
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002064:Buserelin / Q000627:therapeutic use; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy*; D005260:Female; D017273:Goserelin; D006801:Humans; D008593:Menopause
chemical_list: D017273:Goserelin; D002064:Buserelin